Literature DB >> 26851186

STAT3/5-Dependent IL9 Overexpression Contributes to Neoplastic Cell Survival in Mycosis Fungoides.

Pablo A Vieyra-Garcia1, Tianling Wei2, David Gram Naym2, Simon Fredholm3, Regina Fink-Puches1, Lorenzo Cerroni1, Niels Odum3, John T O'Malley4, Robert Gniadecki5, Peter Wolf6.   

Abstract

PURPOSE: Sustained inflammation is a key feature of mycosis fungoides (MF), the most common form of cutaneous T-cell lymphoma (CTCL). Resident IL9-producing T cells have been found in skin infections and certain inflammatory skin diseases, but their role in MF is currently unknown. EXPERIMENTAL
DESIGN: We analyzed lesional skin from patients with MF for the expression of IL9 and its regulators. To determine which cells were producing IL9, high-throughput sequencing was used to identify malignant clones and Vb-specific antibodies were employed to visualize malignant cells in histologic preparations. To explore the mechanism of IL9 secretion, we knocked down STAT3/5 and IRF4 by siRNA transfection in CTCL cell lines receiving psoralen+UVA (PUVA) ± anti-IL9 antibody. To further examine the role of IL9 in tumor development, the EL-4 T-cell lymphoma model was used in C57BL/6 mice.
RESULTS: Malignant and reactive T cells produce IL9 in lesional skin. Expression of the Th9 transcription factor IRF4 in malignant cells was heterogeneous, whereas reactive T cells expressed it uniformly. PUVA or UVB phototherapy diminished the frequencies of IL9- and IL9r-positive cells, as well as STAT3/5a and IRF4 expression in lesional skin. IL9 production was regulated by STAT3/5 and silencing of STAT5 or blockade of IL9 with neutralizing antibodies potentiated cell death after PUVA treatment in vitro IL9-depleted mice exhibited a reduction of tumor growth, higher frequencies of regulatory T cells, and activated CD4 and CD8 T lymphocytes.
CONCLUSIONS: Our results suggest that IL9 and its regulators are promising new targets for therapy development in mycosis fungoides. Clin Cancer Res; 22(13); 3328-39. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26851186      PMCID: PMC4967550          DOI: 10.1158/1078-0432.CCR-15-1784

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  48 in total

1.  STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma.

Authors:  C Brender; M Nielsen; K Kaltoft; G Mikkelsen; Q Zhang; M Wasik; N Billestrup; N Odum
Journal:  Blood       Date:  2001-02-15       Impact factor: 22.113

2.  Interleukin 9 induces expression of three cytokine signal inhibitors: cytokine-inducible SH2-containing protein, suppressor of cytokine signalling (SOCS)-2 and SOCS-3, but only SOCS-3 overexpression suppresses interleukin 9 signalling.

Authors:  D Lejeune; J B Demoulin; J C Renauld
Journal:  Biochem J       Date:  2001-01-01       Impact factor: 3.857

3.  Aberrant activation of interleukin-9 receptor and downstream Stat3/5 in primary T-cell lymphomas in vivo in susceptible B6 and resistant C3H mice.

Authors:  Yi Shang; Shizuko Kakinuma; Yoshiko Amasaki; Mayumi Nishimura; Yoshiro Kobayashi; Yoshiya Shimada
Journal:  In Vivo       Date:  2008 Nov-Dec       Impact factor: 2.155

4.  Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice.

Authors:  Karin Lange; Wolfgang Uckert; Thomas Blankenstein; Roger Nadrowitz; Cordula Bittner; Jean-Christophe Renauld; Jacques van Snick; Alfred C Feller; Hartmut Merz
Journal:  Oncogene       Date:  2003-01-30       Impact factor: 9.867

5.  Mast cells play a protumorigenic role in primary cutaneous lymphoma.

Authors:  Anja Rabenhorst; Max Schlaak; Lukas C Heukamp; Anja Förster; Sebastian Theurich; Michael von Bergwelt-Baildon; Reinhard Büttner; Peter Kurschat; Cornelia Mauch; Axel Roers; Karin Hartmann
Journal:  Blood       Date:  2012-07-26       Impact factor: 22.113

6.  Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056).

Authors:  S Whittaker; P Ortiz; R Dummer; A Ranki; B Hasan; B Meulemans; S Gellrich; R Knobler; R Stadler; M Karrasch
Journal:  Br J Dermatol       Date:  2012-09       Impact factor: 9.302

7.  Immunohistochemical staining for CD45R isoforms in paraffin sections to diagnose mycosis fungoides-type cutaneous T-cell lymphoma.

Authors:  Sahar A Ismail; Rujing Han; Sharon L Sanborn; Seth R Stevens; Kevin D Cooper; Gary S Wood; Anita C Gilliam
Journal:  J Am Acad Dermatol       Date:  2007-04       Impact factor: 11.527

8.  Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes.

Authors:  Linghua Wang; Xiao Ni; Kyle R Covington; Betty Y Yang; Jessica Shiu; Xiang Zhang; Liu Xi; Qingchang Meng; Timothy Langridge; Jennifer Drummond; Lawrence A Donehower; Harshavardhan Doddapaneni; Donna M Muzny; Richard A Gibbs; David A Wheeler; Madeleine Duvic
Journal:  Nat Genet       Date:  2015-11-09       Impact factor: 38.330

9.  The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation.

Authors:  Hua-Chen Chang; Sarita Sehra; Ritobrata Goswami; Weiguo Yao; Qing Yu; Gretta L Stritesky; Rukhsana Jabeen; Carl McKinley; Ayele-Nati Ahyi; Ling Han; Evelyn T Nguyen; Michael J Robertson; Narayanan B Perumal; Robert S Tepper; Stephen L Nutt; Mark H Kaplan
Journal:  Nat Immunol       Date:  2010-05-02       Impact factor: 25.606

10.  Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha.

Authors:  Onur Boyman; Hans Peter Hefti; Curdin Conrad; Brian J Nickoloff; Mark Suter; Frank O Nestle
Journal:  J Exp Med       Date:  2004-02-23       Impact factor: 14.307

View more
  18 in total

1.  Gene expression analysis in Cutaneous T-Cell Lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicators.

Authors:  Ivan V Litvinov; Michael T Tetzlaff; Philippe Thibault; Pamela Gangar; Linda Moreau; Andrew K Watters; Elena Netchiporouk; Kevin Pehr; Victor G Prieto; Elham Rahme; Nathalie Provost; Martin Gilbert; Denis Sasseville; Madeleine Duvic
Journal:  Oncoimmunology       Date:  2017-03-17       Impact factor: 8.110

2.  Evaluation of Low-Dose, Low-Frequency Oral Psoralen-UV-A Treatment With or Without Maintenance on Early-Stage Mycosis Fungoides: A Randomized Clinical Trial.

Authors:  Pablo Vieyra-Garcia; Regina Fink-Puches; Stefanie Porkert; Roland Lang; Sophie Pöchlauer; Gudrun Ratzinger; Adrian Tanew; Sylvia Selhofer; Sator Paul-Gunther; Angelika Hofer; Alexandra Gruber-Wackernagel; Franz Legat; Vijaykumar Patra; Franz Quehenberger; Lorenzo Cerroni; Rachael Clark; Peter Wolf
Journal:  JAMA Dermatol       Date:  2019-05-01       Impact factor: 10.282

Review 3.  TH9 cells in skin disorders.

Authors:  Rachael A Clark; Christoph Schlapbach
Journal:  Semin Immunopathol       Date:  2016-11-28       Impact factor: 9.623

4.  Genome-wide transcriptome analysis of the STAT6-regulated genes in advanced-stage cutaneous T-cell lymphoma.

Authors:  Alyxzandria M Gaydosik; Dawn S Queen; Megan H Trager; Oleg E Akilov; Larisa J Geskin; Patrizia Fuschiotti
Journal:  Blood       Date:  2020-10-08       Impact factor: 22.113

5.  STAT5 induces miR-21 expression in cutaneous T cell lymphoma.

Authors:  Lise M Lindahl; Simon Fredholm; Claudine Joseph; Boye Schnack Nielsen; Lars Jønson; Andreas Willerslev-Olsen; Maria Gluud; Edda Blümel; David L Petersen; Nina Sibbesen; Tengpeng Hu; Claudia Nastasi; Thorbjørn Krejsgaard; Ditte Jæhger; Jenny L Persson; Nigel Mongan; Mariusz A Wasik; Ivan V Litvinov; Denis Sasseville; Sergei B Koralov; Charlotte M Bonefeld; Carsten Geisler; Anders Woetmann; Elisabeth Ralfkiaer; Lars Iversen; Niels Odum
Journal:  Oncotarget       Date:  2016-07-19

6.  Novel phosphorylated TAK1 species with functional impact on NF-κB and β-catenin signaling in human Cutaneous T-cell lymphoma.

Authors:  Fernando Gallardo; Joan Bertran; Erika López-Arribillaga; Jéssica González; Silvia Menéndez; Ignacio Sánchez; Luis Colomo; Mar Iglesias; Marta Garrido; Luis Francisco Santamaría-Babí; Ferran Torres; Ramon M Pujol; Anna Bigas; Lluís Espinosa
Journal:  Leukemia       Date:  2018-02-22       Impact factor: 11.528

7.  NLRP3 Regulates IL-4 Expression in TOX+ CD4+ T Cells of Cutaneous T Cell Lymphoma to Potentially Promote Disease Progression.

Authors:  Enrique Huanosta-Murillo; Marcela Alcántara-Hernández; Brenda Hernández-Rico; Georgina Victoria-Acosta; Patricia Miranda-Cruz; María Antonieta Domínguez-Gómez; Fermín Jurado-Santacruz; Genaro Patiño-López; Vadim Pérez-Koldenkova; Alam Palma-Guzmán; Paula Licona-Limón; Ezequiel M Fuentes-Pananá; Alicia Lemini-López; Laura C Bonifaz
Journal:  Front Immunol       Date:  2021-06-16       Impact factor: 7.561

Review 8.  An overview of cutaneous T cell lymphomas.

Authors:  Nooshin Bagherani; Bruce R Smoller
Journal:  F1000Res       Date:  2016-07-28

9.  A Perspective on the Interplay of Ultraviolet-Radiation, Skin Microbiome and Skin Resident Memory TCRαβ+ Cells.

Authors:  VijayKumar Patra; Léo Laoubi; Jean-François Nicolas; Marc Vocanson; Peter Wolf
Journal:  Front Med (Lausanne)       Date:  2018-05-30

Review 10.  From Early Immunomodulatory Triggers to Immunosuppressive Outcome: Therapeutic Implications of the Complex Interplay Between the Wavebands of Sunlight and the Skin.

Authors:  Pablo A Vieyra-Garcia; Peter Wolf
Journal:  Front Med (Lausanne)       Date:  2018-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.